Hudson Bay Capital Management LP Arbutus Biopharma Corp Transaction History

Hudson Bay Capital Management LP

  • $21.9 Billion
  • Q3 2024

A detailed history of Hudson Bay Capital Management LP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 1,030,000 shares of ABUS stock, worth $3.75 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,030,000
Previous 1,685,000 38.87%
Holding current value
$3.75 Million
Previous $5.21 Million 23.84%
% of portfolio
0.02%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$3.12 - $4.56 $2.04 Million - $2.99 Million
-655,000 Reduced 38.87%
1,030,000 $3.97 Million
Q2 2024

Aug 14, 2024
SELL
$2.52 - $3.63 $4.63 Million - $6.66 Million
-1,835,382 Reduced 52.14%
1,685,000 $5.21 Million
Q1 2024

May 15, 2024
SELL
$2.26 - $2.92 $1.4 Million - $1.81 Million
-619,522 Reduced 14.96%
3,520,382 $9.08 Million
Q4 2023

Feb 14, 2024
SELL
$1.69 - $2.54 $16,900 - $25,400
-10,000 Reduced 0.24%
4,139,904 $10.3 Million
Q3 2023

Nov 14, 2023
BUY
$1.9 - $2.27 $2.48 Million - $2.96 Million
1,302,978 Added 45.77%
4,149,904 $8.42 Million
Q2 2023

Aug 14, 2023
BUY
$2.24 - $3.06 $247,520 - $338,130
110,500 Added 4.04%
2,846,926 $6.55 Million
Q1 2023

May 16, 2023
BUY
$2.23 - $3.1 $278,527 - $387,190
124,900 Added 4.78%
2,736,426 $8.29 Million
Q1 2023

May 15, 2023
SELL
$2.23 - $3.1 $4.99 Million - $6.94 Million
-2,239,890 Reduced 46.17%
2,611,526 $7.91 Million
Q4 2022

Feb 14, 2023
SELL
$1.91 - $2.85 $211,014 - $314,865
-110,479 Reduced 2.23%
4,851,416 $11.3 Million
Q3 2022

Nov 14, 2022
BUY
$1.88 - $2.88 $552,095 - $845,763
293,668 Added 6.29%
4,961,895 $9.48 Million
Q2 2022

Aug 12, 2022
BUY
$1.98 - $3.17 $366,102 - $586,133
184,900 Added 4.12%
4,668,227 $12.7 Million
Q1 2022

May 16, 2022
BUY
$2.42 - $3.98 $6.48 Million - $10.7 Million
2,677,627 Added 148.29%
4,483,327 $13.4 Million
Q4 2021

Feb 14, 2022
BUY
$3.11 - $4.61 $17,727 - $26,277
5,700 Added 0.32%
1,805,700 $7.02 Million
Q2 2021

Aug 16, 2021
BUY
$2.5 - $3.51 $1 Million - $1.4 Million
400,000 Added 28.57%
1,800,000 $5.45 Million
Q1 2021

May 14, 2021
BUY
$3.14 - $4.84 $2.12 Million - $3.27 Million
675,000 Added 93.1%
1,400,000 $4.66 Million
Q4 2020

Feb 12, 2021
BUY
$2.76 - $4.97 $41,400 - $74,550
15,000 Added 2.11%
725,000 $2.57 Million
Q3 2020

Nov 12, 2020
SELL
$1.75 - $6.2 $463,750 - $1.64 Million
-265,000 Reduced 27.18%
710,000 $2.22 Million
Q2 2020

Aug 12, 2020
BUY
$0.91 - $2.36 $159,250 - $413,000
175,000 Added 21.88%
975,000 $1.77 Million
Q1 2020

May 14, 2020
SELL
$1.01 - $3.42 $50,500 - $171,000
-50,000 Reduced 5.88%
800,000 $808,000
Q4 2019

Feb 12, 2020
SELL
$0.87 - $2.89 $39,150 - $130,050
-45,000 Reduced 5.03%
850,000 $2.36 Million
Q3 2019

Nov 13, 2019
BUY
$1.34 - $2.4 $13,400 - $24,000
10,000 Added 1.13%
895,000 $1.37 Million
Q2 2019

Aug 14, 2019
BUY
$1.46 - $4.44 $343,100 - $1.04 Million
235,000 Added 36.15%
885,000 $1.84 Million
Q4 2018

Feb 13, 2019
BUY
$3.5 - $9.66 $1.75 Million - $4.83 Million
500,000 Added 333.33%
650,000 $2.49 Million
Q3 2018

Nov 14, 2018
SELL
$7.85 - $12.35 $274,750 - $432,250
-35,000 Reduced 18.92%
150,000 $1.42 Million
Q2 2018

Aug 13, 2018
SELL
$5.0 - $7.35 $875,000 - $1.29 Million
-175,000 Reduced 48.61%
185,000 $1.35 Million
Q1 2018

May 14, 2018
SELL
$4.4 - $6.05 $176,000 - $242,000
-40,000 Reduced 10.0%
360,000 $1.8 Million
Q4 2017

Feb 12, 2018
BUY
$4.45 - $7.7 $1.25 Million - $2.17 Million
282,000 Added 238.98%
400,000 $2.02 Million
Q3 2017

Nov 13, 2017
BUY
$3.4 - $7.0 $401,200 - $826,000
118,000
118,000 $732,000

Others Institutions Holding ABUS

# of Institutions
156
Shares Held
99.6M
Call Options Held
2.31M
Put Options Held
525K
View Full List

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $546M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email